Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?

Sarah J. Welsh; Helen Rizos; Richard A Scolyer; Georgina V. Long

doi:10.1016/j.ejca.2016.04.005

Related publications

Article2014

New <i>RAS</i>-Mutant Pancreatic Adenocarcinoma With Combined BRAF and MEK Inhibition for Metastatic Melanoma

Matteo S. Carlino, Vu Kwan, David K. Miller, Catherine A.B. Saunders, Desmond Yip, Adnan Nagrial, Jeanne Tomlinson, Sean M. Grimmond, Richard A Scolyer, Richard Kefford, Andrew V. Biankin, Georgina V. Long

Article2014

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma

Georgina V. Long, Carina Fung, Alexander M. Menzies, Gulietta M. Pupo, Matteo S. Carlino, Jessica Hyman, Hamideh Shahheydari, Varsha Tembe, John F. Thompson, Robyn P.M. Saw, Julie R. Howle, Nicholas K. Hayward, Peter A. Johansson, Richard A Scolyer, Richard Kefford, Helen Rizos

Article2017

Abstract 2206: Proteome phenotype of stage III metastatic melanoma and response to MEK inhibition

Christoph Krisp, Robert Parker, Dana Pascovici, James S. Wilmott, John F. Thompson, Graham J. Mann, Richard A Scolyer, Nicholas K. Hayward, Mark P. Molloy

Article2013

AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma

Wanglai Hu, Lei Jin, C C Jiang, Georgina V. Long, Richard A Scolyer, Qingang Wu, Xu Dong Zhang, Yide Mei, Mian Wu

Article2019

The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors

Julia Lai‐Kwon, Chloe Khoo, Serigne Lo, Donna Milne, Mustafa Abdi Mohamed, Jeanette Raleigh, Kortnye Smith, Karolina Lisy, Shahneen Sandhu, Michael Jefford